局限性及晚期肾癌治疗的新进展  

New progress in the treatment of localized and advanced renal cell carcinoma

作　　者：章小平 程功 ZHANG Xiaoping;CHENG Gong(Department of Urology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China;Institute of Urologic Surgery,Tongji Medical College,Huazhong University of Science and Technology)

机构地区：[1]华中科技大学同济医学院附属协和医院泌尿外科,武汉430022 [2]华中科技大学同济医学院泌尿外科研究所

出　　处：《临床泌尿外科杂志》2024年第11期939-943,共5页Journal of Clinical Urology

摘　　要：过去十年,肾细胞癌的治疗格局已经发生了转变,包括在辅助治疗中加入免疫检查点抑制剂的联合疗法。随着近年来临床药物试验的开展,围绕手术、非手术、一线、二线治疗方案仍存在许多争议,包括转移性疾病的治疗选择和风险评估模型的效用。为了在疾病的所有阶段选择最合适的治疗方式,临床工作者和科学家需要更加拓宽视野,例如将目光从IMDC风险预后评估模型转移到个性化生物标志物靶点治疗。文本拟对目前肾细胞癌治疗的新进展展开论述,旨在为局限性及晚期肾癌患者的诊疗工作提供借鉴意义。Over the past decade,the treatment landscape for renal cell carcinoma has shifted,including combination therapies that add immune checkpoint inhibitors to adjuvant therapy.With the development of clinical drug trials in recent years,there are still controversies surrounding surgical,non-surgical,first-line and second-line treatment options,including treatment options for metastatic diseases and the effectiveness of risk assessment models.In order to select the most appropriate treatment at all stages of the disease,clinicians and scientists need to broaden their horizons,such as shifting their focus from IMDC risk and prognosis assessment models to personalized biomarker target therapy.This paper intends to discuss the current new progress in the treatment of renal cell carcinoma,aiming to provide reference for the diagnosis and treatment of patients with localized and advanced renal cancer.

关 键 词：肾细胞癌 手术 靶向 免疫 

分 类 号：R737.11[医药卫生—肿瘤]